[1]
Ungvari GS, Gerevich J, Takács R, Gazdag G. Schizophrenia with prominent catatonic features: A selective review. Schizophrenia research. 2018 Oct:200():77-84. doi: 10.1016/j.schres.2017.08.008. Epub 2017 Aug 14
[PubMed PMID: 28818505]
[2]
Fink M, Shorter E, Taylor MA. Catatonia is not schizophrenia: Kraepelin's error and the need to recognize catatonia as an independent syndrome in medical nomenclature. Schizophrenia bulletin. 2010 Mar:36(2):314-20. doi: 10.1093/schbul/sbp059. Epub 2009 Jul 8
[PubMed PMID: 19586994]
[3]
Caroff SN, Hurford I, Bleier HR, Gorton GE, Campbell EC. Recurrent Idiopathic Catatonia: Implications beyond the Diagnostic and Statistical Manual of Mental Disorders 5th Edition. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. 2015 Aug 31:13(2):218-21. doi: 10.9758/cpn.2015.13.2.218. Epub
[PubMed PMID: 26243853]
[4]
Peralta V, Cuesta MJ, Serrano JF, Mata I. The Kahlbaum syndrome: a study of its clinical validity, nosological status, and relationship with schizophrenia and mood disorder. Comprehensive psychiatry. 1997 Jan-Feb:38(1):61-7
[PubMed PMID: 8980874]
[5]
Francis A. Catatonia: diagnosis, classification, and treatment. Current psychiatry reports. 2010 Jun:12(3):180-5. doi: 10.1007/s11920-010-0113-y. Epub
[PubMed PMID: 20425278]
[6]
Ellul P, Choucha W. Neurobiological Approach of Catatonia and Treatment Perspectives. Frontiers in psychiatry. 2015:6():182. doi: 10.3389/fpsyt.2015.00182. Epub 2015 Dec 24
[PubMed PMID: 26733892]
Level 3 (low-level) evidence
[7]
Francis A, Fink M, Appiani F, Bertelsen A, Bolwig TG, Bräunig P, Caroff SN, Carroll BT, Cavanna AE, Cohen D, Cottencin O, Cuesta MJ, Daniels J, Dhossche D, Fricchione GL, Gazdag G, Ghaziuddin N, Healy D, Klein D, Krüger S, Lee JW, Mann SC, Mazurek M, McCall WV, McDaniel WW, Northoff G, Peralta V, Petrides G, Rosebush P, Rummans TA, Shorter E, Suzuki K, Thomas P, Vaiva G, Wachtel L. Catatonia in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. The journal of ECT. 2010 Dec:26(4):246-7. doi: 10.1097/YCT.0b013e3181fe28bd. Epub
[PubMed PMID: 21099376]
[8]
Rosebush PI, Mazurek MF. Catatonia and its treatment. Schizophrenia bulletin. 2010 Mar:36(2):239-42. doi: 10.1093/schbul/sbp141. Epub 2009 Dec 7
[PubMed PMID: 19969591]
[9]
Kleinhaus K, Harlap S, Perrin MC, Manor O, Weiser M, Harkavy-Friedman JM, Lichtenberg P, Malaspina D. Catatonic schizophrenia: a cohort prospective study. Schizophrenia bulletin. 2012 Mar:38(2):331-7. doi: 10.1093/schbul/sbq087. Epub 2010 Aug 6
[PubMed PMID: 20693343]
[10]
Ungvari GS, Goggins W, Leung SK, Gerevich J. Schizophrenia with prominent catatonic features ('catatonic schizophrenia'). II. Factor analysis of the catatonic syndrome. Progress in neuro-psychopharmacology & biological psychiatry. 2007 Mar 30:31(2):462-8
[PubMed PMID: 17188791]
[11]
Lauer M, Schirrmeister H, Gerhard A, Ellitok E, Beckmann H, Reske SN, Stöber G. Disturbed neural circuits in a subtype of chronic catatonic schizophrenia demonstrated by F-18-FDG-PET and F-18-DOPA-PET. Journal of neural transmission (Vienna, Austria : 1996). 2001:108(6):661-70
[PubMed PMID: 11478418]
[12]
Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. The Lancet. Neurology. 2011 Jan:10(1):63-74. doi: 10.1016/S1474-4422(10)70253-2. Epub
[PubMed PMID: 21163445]
[13]
Sienaert P, Dhossche DM, Vancampfort D, De Hert M, Gazdag G. A clinical review of the treatment of catatonia. Frontiers in psychiatry. 2014:5():181. doi: 10.3389/fpsyt.2014.00181. Epub 2014 Dec 9
[PubMed PMID: 25538636]
[14]
Northoff G, Steinke R, Czcervenka C, Krause R, Ulrich S, Danos P, Kropf D, Otto H, Bogerts B. Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding. Journal of neurology, neurosurgery, and psychiatry. 1999 Oct:67(4):445-50
[PubMed PMID: 10486389]
[15]
Walther S, Strik W. Catatonia. CNS spectrums. 2016 Aug:21(4):341-8. doi: 10.1017/S1092852916000274. Epub 2016 Jun 3
[PubMed PMID: 27255726]
[16]
Walther S, Strik W. Motor symptoms and schizophrenia. Neuropsychobiology. 2012:66(2):77-92. doi: 10.1159/000339456. Epub 2012 Jul 17
[PubMed PMID: 22814247]
[17]
Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. I. Rating scale and standardized examination. Acta psychiatrica Scandinavica. 1996 Feb:93(2):129-36
[PubMed PMID: 8686483]
[18]
Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. II. Treatment with lorazepam and electroconvulsive therapy. Acta psychiatrica Scandinavica. 1996 Feb:93(2):137-43
[PubMed PMID: 8686484]
[19]
Ungvari GS, Chiu HF, Chow LY, Lau BS, Tang WK. Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study. Psychopharmacology. 1999 Mar:142(4):393-8
[PubMed PMID: 10229064]
Level 1 (high-level) evidence
[20]
Narayanaswamy JC, Tibrewal P, Zutshi A, Srinivasaraju R, Math SB. Clinical predictors of response to treatment in catatonia. General hospital psychiatry. 2012 May-Jun:34(3):312-6. doi: 10.1016/j.genhosppsych.2012.01.011. Epub 2012 Mar 2
[PubMed PMID: 22387048]
[21]
Beckmann H, Fritze J, Franzek E. The influence of neuroleptics on specific syndromes and symptoms in schizophrenics with unfavourable long-term course. A 5-year follow-up study of 50 chronic schizophrenics. Neuropsychobiology. 1992:26(1-2):50-8
[PubMed PMID: 1361971]
[22]
Fink M, Taylor MA. Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia. Progress in neuro-psychopharmacology & biological psychiatry. 2006 Aug 30:30(6):1182-3; author reply 1184-5
[PubMed PMID: 16675086]
[23]
Suzuki K, Awata S, Matsuoka H. One-year outcome after response to ECT in middle-aged and elderly patients with intractable catatonic schizophrenia. The journal of ECT. 2004 Jun:20(2):99-106
[PubMed PMID: 15167426]
[25]
Muneoka K, Shirayama Y, Kon K, Kawabe M, Goto M, Kimura S. Improvement of mutism in a catatonic schizophrenia case by add-on treatment with amantadine. Pharmacopsychiatry. 2010 Jun:43(4):151-2. doi: 10.1055/s-0029-1242821. Epub 2009 Dec 16
[PubMed PMID: 20571993]
Level 3 (low-level) evidence
[26]
Petursson H. Lithium treatment of a patient with periodic catatonia. Acta psychiatrica Scandinavica. 1976 Oct:54(4):248-53
[PubMed PMID: 998323]
[27]
Lee JW, Schwartz DL, Hallmayer J. Catatonia in a psychiatric intensive care facility: incidence and response to benzodiazepines. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 2000 Jun:12(2):89-96
[PubMed PMID: 10907800]
[28]
Rohland BM, Carroll BT, Jacoby RG. ECT in the treatment of the catatonic syndrome. Journal of affective disorders. 1993 Dec:29(4):255-61
[PubMed PMID: 8126312]
[29]
Ungvari GS, Caroff SN, Gerevich J. The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders. Schizophrenia bulletin. 2010 Mar:36(2):231-8. doi: 10.1093/schbul/sbp105. Epub 2009 Sep 23
[PubMed PMID: 19776208]
[30]
Ungvari GS, Leung SK, Ng FS, Cheung HK, Leung T. Schizophrenia with prominent catatonic features ('catatonic schizophrenia'): I. Demographic and clinical correlates in the chronic phase. Progress in neuro-psychopharmacology & biological psychiatry. 2005 Jan:29(1):27-38
[PubMed PMID: 15610942]
[31]
Clinebell K, Azzam PN, Gopalan P, Haskett R. Guidelines for preventing common medical complications of catatonia: case report and literature review. The Journal of clinical psychiatry. 2014 Jun:75(6):644-51. doi: 10.4088/JCP.13r08870. Epub
[PubMed PMID: 25004188]
Level 3 (low-level) evidence